MX2019013734A - Inhibidores y antagonistas de gpr84 para el tratamiento de endometriosis. - Google Patents

Inhibidores y antagonistas de gpr84 para el tratamiento de endometriosis.

Info

Publication number
MX2019013734A
MX2019013734A MX2019013734A MX2019013734A MX2019013734A MX 2019013734 A MX2019013734 A MX 2019013734A MX 2019013734 A MX2019013734 A MX 2019013734A MX 2019013734 A MX2019013734 A MX 2019013734A MX 2019013734 A MX2019013734 A MX 2019013734A
Authority
MX
Mexico
Prior art keywords
gpr84
endometriosis
treatment
antagonists
inhibitors
Prior art date
Application number
MX2019013734A
Other languages
English (en)
Inventor
Langer Gernot
Sacher Frank
Obendorf Maik
Martinez Estrada Fernando
Oppermann Udo
Shang Catherine
Original Assignee
Bayer Pharma AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Pharma AG filed Critical Bayer Pharma AG
Publication of MX2019013734A publication Critical patent/MX2019013734A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/689—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to pregnancy or the gonads
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Gynecology & Obstetrics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a un antagonista o inhibidor del receptor 84 acoplado a proteína G (GPR84) para utilizar en el tratamiento y/o prevención de un paciente que padece endometriosis, que está en riesgo de desarrollar dicha enfermedad, y/o que está siendo diagnosticado para endometriosis, así como también métodos de selección de dicho antagonista o inhibidor así como también métodos para el diagnóstico.
MX2019013734A 2017-05-16 2018-05-15 Inhibidores y antagonistas de gpr84 para el tratamiento de endometriosis. MX2019013734A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP17171351.4A EP3403649A1 (en) 2017-05-16 2017-05-16 Inhibitors and antagonists of gpr84 for the treatment of endometriosis
PCT/EP2018/062544 WO2018210822A1 (en) 2017-05-16 2018-05-15 Inhibitors and antagonists of gpr84 for the treatment of endometriosis

Publications (1)

Publication Number Publication Date
MX2019013734A true MX2019013734A (es) 2020-01-15

Family

ID=58745052

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019013734A MX2019013734A (es) 2017-05-16 2018-05-15 Inhibidores y antagonistas de gpr84 para el tratamiento de endometriosis.

Country Status (14)

Country Link
US (1) US20210401823A1 (es)
EP (2) EP3403649A1 (es)
JP (1) JP2020519662A (es)
KR (1) KR20200003830A (es)
CN (1) CN110573146A (es)
AR (1) AR111801A1 (es)
AU (1) AU2018269328A1 (es)
BR (1) BR112019023999A2 (es)
CA (1) CA3063489A1 (es)
MX (1) MX2019013734A (es)
PE (1) PE20191746A1 (es)
SG (1) SG11201909783VA (es)
TW (1) TW201900214A (es)
WO (1) WO2018210822A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111012782B (zh) * 2019-12-27 2023-08-04 郑州大学第一附属医院 一种g蛋白偶联受体gpr84抑制剂及其应用
EP4110056A4 (en) * 2020-02-25 2024-05-01 Texas A & M Univ Sys METHODS OF TREATING ENDOMETRIOSIS

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
CA2229043C (en) 1995-08-18 2016-06-07 Morphosys Gesellschaft Fur Proteinoptimierung Mbh Protein/(poly)peptide libraries
US7053202B2 (en) 2001-10-19 2006-05-30 Millennium Pharmaceuticals, Inc. Immunoglobulin DNA cassette molecules, monobody constructs, methods of production, and methods of use therefor
WO2003073843A2 (en) 2002-03-05 2003-09-12 Artemis Pharmaceuticals Gmbh Inbred embryonic stem-cell derived mice
GB0414798D0 (en) * 2004-07-01 2004-08-04 Paradigm Therapeutics Ltd Receptor
US8691498B2 (en) 2005-09-02 2014-04-08 Arena Pharmaceuticals, Inc. Methods of screening for a compound that reduces atherogenesis
TW200732350A (en) 2005-10-21 2007-09-01 Amgen Inc Methods for generating monovalent IgG
AR089284A1 (es) * 2011-12-22 2014-08-13 Galapagos Nv Dihidropirimidinoisoquinolinonas y composiciones farmaceuticas de las mismas para el tratamiento de trastornos inflamatorios
GB201122146D0 (en) 2011-12-22 2012-02-01 Galapagos Nv Screening methods to identify compounds useful in the prevention and/or treatment of inflammatory conditions
CN104870445B (zh) * 2012-12-20 2017-09-15 加拉帕戈斯股份有限公司 用于治疗炎性疾病的新二氢嘧啶并异喹啉酮类及其药物组合物(gpr84拮抗剂)
GB201411241D0 (en) 2014-06-25 2014-08-06 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders
GB201506894D0 (en) * 2015-04-23 2015-06-10 Galapagos Nv Novel dihydropyridoisoquinolinones and pharmaceutical compositions thereof for the treatment of inflammatory disorders

Also Published As

Publication number Publication date
PE20191746A1 (es) 2019-12-12
SG11201909783VA (en) 2019-11-28
BR112019023999A2 (pt) 2020-06-30
AU2018269328A1 (en) 2019-11-07
KR20200003830A (ko) 2020-01-10
CN110573146A (zh) 2019-12-13
TW201900214A (zh) 2019-01-01
US20210401823A1 (en) 2021-12-30
CA3063489A1 (en) 2018-11-22
EP3403649A1 (en) 2018-11-21
AR111801A1 (es) 2019-08-21
EP3624781A1 (en) 2020-03-25
JP2020519662A (ja) 2020-07-02
WO2018210822A1 (en) 2018-11-22

Similar Documents

Publication Publication Date Title
PH12018500086A1 (en) Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JOP20200122B1 (ar) مركبات مفيدة لتثبيط cdk7
MX2017009047A (es) Regimen de dosificacion para antagonistas de madcam.
MY187053A (en) Envenomation therapies and related pharmaceutical compositions, systems and kits
PH12021550882A1 (en) Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
SG163564A1 (en) Kinin antagonists for treating bladder dysfunction
MX2022000397A (es) Inhibidores peptídicos del receptor de interleucina-23 y su uso para tratar enfermedades inflamatorias.
PH12016502445A1 (en) Antibodies directed against cd127
MX2020013808A (es) Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
EA029499B9 (ru) Ингибиторы rorc2 и способы их применения
NZ738389A (en) Inhibitor of igfbp3/tmem219 axis and diabetes
WO2016030334A3 (en) Methods, agents and compositions for treatment of inflammatory conditions
IL285267A (en) Antibodies associated with an infected form of calreticulin mutation and preventive diagnostics, or treatment factor for neoplasmic myeloproliferative
MX2019013734A (es) Inhibidores y antagonistas de gpr84 para el tratamiento de endometriosis.
PH12018500282A1 (en) Cgrp receptor antagonists
MX2020002216A (es) Metodos y composiciones para detectar y tratar endometriosis.
MX2019001467A (es) Combinación de antagonistas del receptor de glucagon e inhibidores de la trayectoria p13k para el tratamiento del cáncer.
EA201791480A1 (ru) Новые производные бензимидазола в качестве антигистаминных агентов
EA201290851A1 (ru) Способы и композиции для лечения или предупреждения симптомов гормональных изменений
WO2015169884A3 (en) Compounds and methods for the treatment of itch
EA201892583A1 (ru) Комбинация чистых антагонистов 5-htрецептора с антагонистом nmda рецептора
EA201892528A1 (ru) Трехкомпонентная комбинация чистых антагонистов 5-htрецепторов, ингибиторов ацетилхолинэстеразы и антагониста nmda рецептора
PH12019500075A1 (en) Dosage regimens of lingo-1 antagonists and uses for treatment of demyelinating disorders
EP3849604A4 (en) METHODS OF REDUCING INFLUENCE-INDUCED LETHALITY USING GASTRIN-RELEASING PEPTIDE (GRP) INHIBITORS OR GASTRIN-RELEASING PEPTIDE RECEPTOR (GRPR) ANTAGONISTS
EA202092853A1 (ru) РЕЖИМ ДОЗИРОВАНИЯ АНТАГОНИСТОВ MAdCAM